Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
| Molecular Weight | 380.4 g/mol |
|---|---|
| Molecular Formula | C19H14F2N6O |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Exact Mass | 380.11971542 g/mol |
| Monoisotopic Mass | 380.11971542 g/mol |
| Topological Polar Surface Area | 84.2 A^2 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 826 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Talzenna (talazoparib) is a PARP inhibitor, which is approved for the treatment of BRCA gene mutation-positive castration-resistant prostate cancer with distant metastases.
Lead Product(s): Talazoparib
Therapeutic Area: Oncology Brand Name: Talzenna
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Lead Product(s) : Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Chugai Gets Approval for FoundationOne CDx as Companion Diagnostic for Talazoparib
Details : Talzenna (talazoparib) is a PARP inhibitor, which is approved for the treatment of BRCA gene mutation-positive castration-resistant prostate cancer with distant metastases.
Brand Name : Talzenna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 05, 2024
Details:
Talzenna (talazoparib) combined with Xtandi (enzalutamide) is approved by EMA for treating metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Brand Name: Talzenna
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Lead Product(s) : Talazoparib,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Approves Pfizer’s TALZENNA® with XTANDI®
Details : Talzenna (talazoparib) combined with Xtandi (enzalutamide) is approved by EMA for treating metastatic castration-resistant prostate cancer (mCRPC).
Brand Name : Talzenna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2024
Details:
Talzenna (talazoparib) is an oral inhibitor of PARP, which plays a role in DNA damage repair combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Brand Name: Talzenna
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: TFS Trial Form Support
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Lead Product(s) : Talazoparib,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : TFS Trial Form Support
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer’s TALZENNA in Combination with XTANDI Receives U.S. FDA Approval
Details : Talzenna (talazoparib) is an oral inhibitor of PARP, which plays a role in DNA damage repair combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistan...
Brand Name : Talzenna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2023
Details:
Talzenna (talazoparib) is an oral PARP inhibitor, which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to cancer cell apoptosis.
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Brand Name: Talzenna
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Lead Product(s) : Talazoparib,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Details : Talzenna (talazoparib) is an oral PARP inhibitor, which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to cancer cell apoptosis.
Brand Name : Talzenna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 16, 2023
Details:
CX-5461 (pidnarulex) stabilizes the DNA G-quadruplexes of cancer cells which leads to disruption of the cell's replication fork. Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1/2 and PALB2 mutations.
Lead Product(s): Pidnarulex,Talazoparib
Therapeutic Area: Oncology Brand Name: CX-5461
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CX-5461 (pidnarulex) stabilizes the DNA G-quadruplexes of cancer cells which leads to disruption of the cell's replication fork. Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1...
Brand Name : CX-5461
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 31, 2022
Details:
TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor met its primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared with placebo plus XTANDI.
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Brand Name: Talzenna
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Lead Product(s) : Talazoparib,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
Details : TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor met its primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared with placebo plus XTAN...
Brand Name : Talzenna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2022
Details:
ART4215 is first selective, oral, small molecule inhibitor of Polθ polymerase domain to enter clinic. Polθ, a DNA polymerase, is a tumor-specific DDR target involved in MMEJ that is overexpressed in many tumors and found in low levels in healthy tissue.
Lead Product(s): ART4215,Talazoparib
Therapeutic Area: Oncology Brand Name: ART4215
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Lead Product(s) : ART4215,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talaz...
Details : ART4215 is first selective, oral, small molecule inhibitor of Polθ polymerase domain to enter clinic. Polθ, a DNA polymerase, is a tumor-specific DDR target involved in MMEJ that is overexpressed in many tumors and found in low levels in healthy tissue...
Brand Name : ART4215
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2022
Details:
ZEN-3694 (ZEN003694), orally bioavailable small molecule, in initro studies selectively binds to BET proteins with >20 fold selectivity over non-BET bromodomains inhibiting interaction of acetylated histone peptide with IC50 values in low nM range.
Lead Product(s): ZEN003694,Talazoparib
Therapeutic Area: Oncology Brand Name: ZEN-3694
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Lead Product(s) : ZEN003694,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ZEN-3694 (ZEN003694), orally bioavailable small molecule, in initro studies selectively binds to BET proteins with >20 fold selectivity over non-BET bromodomains inhibiting interaction of acetylated histone peptide with IC50 values in low nM range.
Brand Name : ZEN-3694
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2022
Details:
The combination regimen of ZEN-3694 (ZEN003694) + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need. This combination is active with a manageable safety profile and warrants continued clinical evaluation.
Lead Product(s): ZEN-3694,Talazoparib
Therapeutic Area: Oncology Brand Name: ZEN003694
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Lead Product(s) : ZEN-3694,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The combination regimen of ZEN-3694 (ZEN003694) + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need. This combination is active with a manageable safety profile and warrants continued clinical eva...
Brand Name : ZEN003694
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2022
Details:
CX-5461 (Pidnarulex) demonstrated clinically significant and persist benefits in patients with specific tumor biomarkers, such as BRCA1/2, and PALB2 mutations, and who had been exposed to platinum and other chemotherapeutics.
Lead Product(s): Pidnarulex,Talazoparib
Therapeutic Area: Oncology Brand Name: CX-5461
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CX-5461 (Pidnarulex) demonstrated clinically significant and persist benefits in patients with specific tumor biomarkers, such as BRCA1/2, and PALB2 mutations, and who had been exposed to platinum and other chemotherapeutics.
Brand Name : CX-5461
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Norway
Brand Name : Talzenna
Dosage Form : Kapsel, hard
Dosage Strength : 0.1 mg
Packaging : Boks 30item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Talzenna
Dosage Form : Caps
Dosage Strength : 0.25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Talzenna
Dosage Form : Caps
Dosage Strength : 1mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Norway
Brand Name : Talzenna
Dosage Form : Kapsel, hard
Dosage Strength : 0.1 mg
Packaging : Boks 30item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Talzenna
Dosage Form : Caps
Dosage Strength : 0.25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Talzenna
Dosage Form : Caps
Dosage Strength : 1mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
